Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Study acronym: TRITON-PN
StatusRecruiting
PhasePhase 3
Started2026-02-03
View on ClinicalTrials.gov ↗

Amendment history

2026-09-16
Trial sites expanded: 48 → 56 locations
2026-08-12
Study Status, Contacts/Locations v7
Trial sites expanded: 41 → 48 locations
2026-07-22
Study Status, Contacts/Locations v6
Trial sites expanded: 29 → 41 locations
2026-06-10
Study Status, Contacts/Locations v5
Trial sites expanded: 16 → 29 locations
2026-05-12
Study Status, Contacts/Locations v4
Trial sites expanded: 4 → 16 locations
2026-04-16
Study Status, Contacts/Locations v3
Trial sites expanded: 1 → 4 locations
Start dateestimated 2026-01-16→confirmed 2025-12-12
2026-01-12
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2025-12-31→2026-01-16
Study sites0→1
2025-12-18
Study Status v1
Re-verified, no change to tracked fields
2025-10-29
Original filing
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Trial Details
NCT Number NCT07223203
Lead Sponsor Alnylam Pharmaceuticals
Conditions Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
Enrollment 125 participants
Start Date 2026-02-03
Primary Completion 2027-12-27 (estimated)
Study Completion 2031-06-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-15